TechMatrix Corporation
Notice Regarding Basic Agreement for Acquisition of Shares of Medmain Inc. to Make It a Consolidated Subsidiary
TechMatrix Corporation and its consolidated subsidiary PSP Corporation have concluded a basic agreement on February 17, 2026, to acquire shares of Medmain Inc. for approximately 2.3 billion yen, aiming to hold a majority of voting rights and make it a consolidated subsidiary.
Key Figures
- Acquisition Amount: Approximately 2.3 billion yen (planned)
- Percentage of Voting Rights Owned (Post-Acquisition): Over 70% (planned)
- Scheduled Date for Share Transfer Agreement Signing: 2026-04-01
AI要約
Overview of the M&A
TechMatrix Corporation and its consolidated subsidiary PSP Corporation have signed a basic agreement on February 17, 2026, to acquire shares of Medmain Inc. for approximately 2.3 billion yen, aiming to hold a majority of voting rights and make it a consolidated subsidiary. Medmain develops and operates AI software that supports digital pathological diagnosis. Through this share acquisition, TechMatrix will promote the development and commercialization of a digital pathological diagnosis platform highly integrated with AI technology. The expected percentage of voting rights owned after acquisition is over 70%.
Strategic Significance and Future Outlook
This initiative aligns with the TechMatrix Group's medium-term management plan emphasizing "business domain expansion," "growth in overseas markets," and "creating businesses utilizing data." It aims to accelerate the promotion of DX in the pathology field within the medical systems business and expansion of AI-assisted image diagnosis services. The share transfer agreement is scheduled to be signed on April 1, 2026, with the execution expected by the end of April. Any impact on consolidated earnings will be disclosed promptly once confirmed.
